vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and INDEPENDENT BANK CORP (INDB). Click either name above to swap in a different company.
ACADIA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($284.0M vs $212.5M, roughly 1.3× INDEPENDENT BANK CORP). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs 35.5%, a 60.9% gap on every dollar of revenue. On growth, INDEPENDENT BANK CORP posted the faster year-over-year revenue change (46.9% vs 9.4%). Over the past eight quarters, INDEPENDENT BANK CORP's revenue compounded faster (24.3% CAGR vs 17.5%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Independent Bank is a bank headquartered in Grand Rapids, Michigan. The bank has 62 branches, all of which are in Michigan.
ACAD vs INDB — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $212.5M |
| Net Profit | $273.6M | $75.3M |
| Gross Margin | 90.8% | — |
| Operating Margin | 6.1% | — |
| Net Margin | 96.3% | 35.5% |
| Revenue YoY | 9.4% | 46.9% |
| Net Profit YoY | 90.3% | 50.6% |
| EPS (diluted) | $1.61 | $1.51 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | $212.5M | ||
| Q3 25 | $278.6M | $203.3M | ||
| Q2 25 | $264.6M | $147.5M | ||
| Q1 25 | $244.3M | $145.5M | ||
| Q4 24 | $259.6M | $144.7M | ||
| Q3 24 | $250.4M | $141.7M | ||
| Q2 24 | $242.0M | $137.9M | ||
| Q1 24 | $205.8M | $137.4M |
| Q4 25 | $273.6M | $75.3M | ||
| Q3 25 | $71.8M | $34.3M | ||
| Q2 25 | $26.7M | $51.1M | ||
| Q1 25 | $19.0M | $44.4M | ||
| Q4 24 | $143.7M | $50.0M | ||
| Q3 24 | $32.8M | $42.9M | ||
| Q2 24 | $33.4M | $51.3M | ||
| Q1 24 | $16.6M | $47.8M |
| Q4 25 | 90.8% | — | ||
| Q3 25 | 92.2% | — | ||
| Q2 25 | 92.2% | — | ||
| Q1 25 | 91.7% | — | ||
| Q4 24 | 91.6% | — | ||
| Q3 24 | 92.5% | — | ||
| Q2 24 | 92.5% | — | ||
| Q1 24 | 88.8% | — |
| Q4 25 | 6.1% | — | ||
| Q3 25 | 12.8% | 21.8% | ||
| Q2 25 | 12.2% | 44.6% | ||
| Q1 25 | 7.9% | 39.3% | ||
| Q4 24 | 59.1% | — | ||
| Q3 24 | 12.6% | 39.0% | ||
| Q2 24 | 12.6% | 48.1% | ||
| Q1 24 | 7.4% | 45.5% |
| Q4 25 | 96.3% | 35.5% | ||
| Q3 25 | 25.8% | 16.8% | ||
| Q2 25 | 10.1% | 34.6% | ||
| Q1 25 | 7.8% | 30.5% | ||
| Q4 24 | 55.4% | 34.6% | ||
| Q3 24 | 13.1% | 30.3% | ||
| Q2 24 | 13.8% | 37.2% | ||
| Q1 24 | 8.0% | 34.8% |
| Q4 25 | $1.61 | $1.51 | ||
| Q3 25 | $0.42 | $0.69 | ||
| Q2 25 | $0.16 | $1.20 | ||
| Q1 25 | $0.11 | $1.04 | ||
| Q4 24 | $0.86 | $1.18 | ||
| Q3 24 | $0.20 | $1.01 | ||
| Q2 24 | $0.20 | $1.21 | ||
| Q1 24 | $0.10 | $1.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $3.6B |
| Total Assets | $1.6B | $24.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | — | ||
| Q3 25 | $258.0M | — | ||
| Q2 25 | $253.6M | — | ||
| Q1 25 | $217.7M | — | ||
| Q4 24 | $319.6M | — | ||
| Q3 24 | $155.1M | — | ||
| Q2 24 | $177.1M | — | ||
| Q1 24 | $204.7M | — |
| Q4 25 | $1.2B | $3.6B | ||
| Q3 25 | $917.3M | $3.5B | ||
| Q2 25 | $822.4M | $3.1B | ||
| Q1 25 | $765.2M | $3.0B | ||
| Q4 24 | $732.8M | $3.0B | ||
| Q3 24 | $577.2M | $3.0B | ||
| Q2 24 | $516.7M | $2.9B | ||
| Q1 24 | $464.0M | $2.9B |
| Q4 25 | $1.6B | $24.9B | ||
| Q3 25 | $1.3B | $25.0B | ||
| Q2 25 | $1.2B | $20.0B | ||
| Q1 25 | $1.1B | $19.9B | ||
| Q4 24 | $1.2B | $19.4B | ||
| Q3 24 | $976.9M | $19.4B | ||
| Q2 24 | $914.1M | $19.4B | ||
| Q1 24 | $855.1M | $19.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $78.9M |
| Free Cash FlowOCF − Capex | — | $75.5M |
| FCF MarginFCF / Revenue | — | 35.5% |
| Capex IntensityCapex / Revenue | — | 1.6% |
| Cash ConversionOCF / Net Profit | -0.18× | 1.05× |
| TTM Free Cash FlowTrailing 4 quarters | — | $239.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | $78.9M | ||
| Q3 25 | $74.3M | $52.2M | ||
| Q2 25 | $64.0M | $106.7M | ||
| Q1 25 | $20.3M | $13.3M | ||
| Q4 24 | $40.4M | $42.9M | ||
| Q3 24 | $63.2M | $70.2M | ||
| Q2 24 | $25.0M | $65.6M | ||
| Q1 24 | $29.1M | $51.1M |
| Q4 25 | — | $75.5M | ||
| Q3 25 | $73.9M | $49.7M | ||
| Q2 25 | — | $102.5M | ||
| Q1 25 | — | $11.3M | ||
| Q4 24 | — | $36.5M | ||
| Q3 24 | $63.2M | $64.4M | ||
| Q2 24 | — | $61.9M | ||
| Q1 24 | — | $46.7M |
| Q4 25 | — | 35.5% | ||
| Q3 25 | 26.5% | 24.4% | ||
| Q2 25 | — | 69.5% | ||
| Q1 25 | — | 7.8% | ||
| Q4 24 | — | 25.2% | ||
| Q3 24 | 25.2% | 45.4% | ||
| Q2 24 | — | 44.9% | ||
| Q1 24 | — | 34.0% |
| Q4 25 | — | 1.6% | ||
| Q3 25 | 0.1% | 1.2% | ||
| Q2 25 | — | 2.9% | ||
| Q1 25 | — | 1.4% | ||
| Q4 24 | — | 4.4% | ||
| Q3 24 | 0.0% | 4.1% | ||
| Q2 24 | — | 2.7% | ||
| Q1 24 | — | 3.2% |
| Q4 25 | -0.18× | 1.05× | ||
| Q3 25 | 1.03× | 1.52× | ||
| Q2 25 | 2.40× | 2.09× | ||
| Q1 25 | 1.07× | 0.30× | ||
| Q4 24 | 0.28× | 0.86× | ||
| Q3 24 | 1.93× | 1.64× | ||
| Q2 24 | 0.75× | 1.28× | ||
| Q1 24 | 1.76× | 1.07× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
INDB
Segment breakdown not available.
